The power of strategic data standardization

The pharmaceutical industry is deluged with data. However, because data is seldom standardized, companies cannot fully tap its potential to substantially reduce the failure rates in drug development. [1] By consciously streamlining and unifying data, drugmakers can improve efficiency throughout […]

Read More

Drug development in rare diseases

In the United States, a rare disease is defined as a condition that affects fewer than 200,000 people, while in the European Union, a disease is defined as rare when it affects fewer than one in 2,000 people. The US […]

Read More

PCI adds to cold chain capacity in Philadelphia

PCI Pharma Services, a contract development and manufacturing organization (CDMO) has announced a 60% expansion of temperature-controlled storage space, from the equivalent of 800 pallet spaces to over 1,300. That 2-8°C storage is primarily to stage commercial production or largescale […]

Read More

CVS readies a set of outcomes-based contracts for its clients

While announcing its annual update of drugs (now around 36) to be excluded from its “Standard Control Formulary” in 2018, the industry-leading pharmacy benefit manager (PBM) is also hinting at another cost-control measure: outcomes-based contracting. Such programs have been occasionally entered […]

Read More